Technology
Tubulysins and their synthetic analogues the Cytolysins show exceptional high cytotoxic activity against many tumor cell lines, including multiple drug resistant cell lines. They are orders of magnitude more potent than other marketed cytotoxics. Moreover, Tubulysins show an exceptional potent anti-angiogenic profile.
Because of their high activity they perfectly suited for any kind of conjugation. Thus, they have high promise in the targeted therapy of cancer and other diseases.
R&D News
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010